0001968582-23-000263.txt : 20230620
0001968582-23-000263.hdr.sgml : 20230620
20230620165255
ACCESSION NUMBER: 0001968582-23-000263
CONFORMED SUBMISSION TYPE: 144
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20230620
DATE AS OF CHANGE: 20230620
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc.
CENTRAL INDEX KEY: 0001806310
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 843199512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 144
SEC ACT: 1933 Act
SEC FILE NUMBER: 001-39536
FILM NUMBER: 231025958
BUSINESS ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
BUSINESS PHONE: (214) 612-0000
MAIL ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
REPORTING-OWNER:
COMPANY DATA:
COMPANY CONFORMED NAME: Session R.A. II
CENTRAL INDEX KEY: 0001701846
FILING VALUES:
FORM TYPE: 144
MAIL ADDRESS:
STREET 1: C/O AVEXIS, INC.
STREET 2: 2275 HALF DAY ROAD, SUITE 200
CITY: BANNOCKBURN
STATE: IL
ZIP: 60015
144
1
primary_doc.xml
144
0001701846
XXXXXXXX
LIVE
0001806310
Taysha Gene Therapies Inc
001-39536
3000 Pegasus Park Drive
Suite 1430
Dallas
TX
75247
212-612-0000
R.A. Sessions II
Affiliate
Common
J.P. Morgan Securities LLC
390 Madison Avenue
6th Floor
New York
NY
10017
1006000
699572.4
64178567
06/20/2023
Nasdaq
Common
09/23/2020
Founder Shares
Issuer
N
1006000
09/23/2020
N/A
Y
06/20/2023
/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for R.A. Sessions II